Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead Reports $27.8 Million Q3 Revenue and $175.2 Million Net Loss

Mixed Impact 4 of 5 earnings Written later

Arrowhead Pharmaceuticals reported results for the fiscal 2025 third quarter ended June 30, 2025, with revenue of $27.8 million compared with none a year earlier. The net loss attributable to the company was $175.2 million, up from $170.8 million, while the diluted loss per share narrowed to $1.26 from $1.38. The filing also described a $130 million upfront payment from Sanofi tied to a Greater China deal for a majority-owned subsidiary, and a $100 million Sarepta milestone payment.

Key points

  • Revenue of $27.8 million in the quarter, versus $0 in the same period a year earlier
  • Net loss attributable to Arrowhead of $175.2 million, versus $170.8 million a year earlier; diluted loss per share of $1.26, versus $1.38
  • Research and development expenses of $162.4 million and general and administrative expenses of $30.9 million
  • Total cash resources of $900.4 million as of June 30, 2025, and a PDUFA action date of November 18, 2025 for plozasiran

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECAug 7, 2025, 4:07 PM ET
Accession number0001628280-25-038867

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.